Allergy Therapeutics PLC Result of General Meeting and Issue of Equity (8507I)
30 March 2015 - 9:27PM
UK Regulatory
TIDMAGY
RNS Number : 8507I
Allergy Therapeutics PLC
30 March 2015
30 March 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Result of General Meeting and Issue of Equity
On 10 March 2015, Allergy Therapeutics, the fully integrated
specialty pharmaceutical company specialising in allergy vaccines,
announced plans to raise GBP20.0 million (after expenses) through
the issue of 94,117,650 new ordinary shares in the capital of the
Company (the "Placing Shares") at 22.1 pence per share (the
"Placing"). The Placing is conditional upon, among other things,
shareholder approval and admission of the Placing Shares to trading
on AIM becoming effective. The Company is pleased to announce that,
at a general meeting of its shareholders today, the resolutions
required to authorise the issue of the Placing Shares and the
disapplication of statutory pre-emption rights in relation thereto
were passed. The Placing Shares will be allotted and issued
credited as fully paid and will be identical to and rank parri
passu in all respects with the existing ordinary shares in the
capital of the Company ("Ordinary Shares").
The 4,042,489 convertible loan notes which were issued pursuant
to a convertible loan note instrument executed by the Company on 30
March 2012, as amended, and which are held by CFR International SpA
(as detailed in a circular published by the Company on 30 March
2012(1) ) will be converted into 41,674,938 new Ordinary Shares
(the "Conversion Shares") at 9.7 pence per share on 31 March 2015
in accordance with their terms. The Conversion Shares will be
allotted and issued conditional upon their admission to trading on
AIM becoming effective, credited as fully paid and will be
identical to and rank parri passu in all respects with the existing
Ordinary Shares.
An application has been made to the London Stock Exchange plc
for the Placing Shares and the Conversion Shares to be admitted to
trading on AIM and it is expected that admission will become
effective in respect of, and that dealings on AIM will commence in,
the Placing Shares and the Conversion Shares at 8.00 a.m. on 1
April 2015.
Allergy Therapeutics' enlarged issued ordinary share capital
immediately following the admission of the Placing Shares and the
Conversion Shares will consist of 545,847,919 Ordinary Shares with
voting rights attached (one vote per Ordinary Share). The Company
has no shares in Treasury; therefore the total number of voting
rights in Allergy Therapeutics is 545,847,919. This figure may be
used by shareholders as the denominator for the calculations by
which they will determine whether they are required to notify their
interests in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure and Transparency
Rules.
+44 (0) 1903 845
Allergy Therapeutics 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
+44 (0) 20 7886
Panmure Gordon 2500
Freddy Crossley / Peter Steel / Duncan Monteith,
Corporate Finance
Tom Salvesen, Corporate Broking
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway
Victoria Foster Mitchell
(1) The 2012 Circular is available to view on the Company's
website.
The distribution of this announcement in jurisdictions other
than the United Kingdom may be restricted by law and therefore
persons into whose possession this document and/or accompanying
documents come should inform themselves about and observe any such
restrictions. Any failure to comply with any such restrictions may
constitute a violation of the securities laws or regulations of
such jurisdictions. In particular, subject to certain exceptions,
this announcement should not be distributed, forwarded to or
transmitted in or into the United States (as defined in Regulation
S of the United States Securities Act of 1933, as amended
("Regulation S") or Australia, Canada, Japan, the Republic of South
Africa and New Zealand (the "Excluded Jurisdictions"). None of the
Placing Shares have been, nor will they be, registered in the
United States under the United States Securities Act of 1933 (the
"Securities Act"), as amended, or under the securities laws of any
of the Excluded Jurisdictions and, subject to certain exceptions,
they may not be offered or sold directly or indirectly within or
into the Excluded Jurisdictions or to, or for the account or
benefit of, any national, citizen or resident of the Excluded
Jurisdictions. Subject to certain exceptions, none of the Placing
Shares may be offered or sold, directly or indirectly, in the
United States or to, or for the account or benefit of, U.S. persons
(as such terms are defined in Regulation S under the Securities
Act). This announcement does not constitute an offer to sell or
issue or the solicitation of an offer to buy or subscribe for
Placing Shares in any jurisdiction in which such offer or
solicitation is unlawful.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBBLFXEXFLBBE
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024